Pipeline Previews

March 2014 | Volume 13 | Issue 3 | Features | 368 | Copyright © March 2014


Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.

Skin Tightening with Thermi

ThermiAestheticsTM Southlake, TX, announced the publication of a clinical study analyzing the ThermiRFTM system, the first FDA cleared temperature controlled radiofrequency system designed for cosmetic applications. The study, which appeared in the February issue of the Journal of Drugs in Dermatology, treated submental skin laxity in 18 subjects using thermistor-controlled subdermal skin tightening (Thermi- TightTM) via percutaneous radiofrequency.
“The data from the study demonstrates the safety and effectiveness of a micro-invasive, office-based solution for patients with laxity in the lower face and neck,” said Paul Herchman, Chief Executive Officer of ThermiAesthetics. “The combination of thermistor-regulated energy delivery and the simultaneous monitoring of subdermal and external temperatures, enables physicians to safely produce a single treatment result, with little or no downtime, which has not previously been possible.”
A gradual decline in collagen and elastin in the skin over time can lead to excess skin laxity. This loss of skin quality can be a barometer of age, driving patient demand for skin restoration procedures. A growing number of aging baby boomers are seeking a solution for advanced skin laxity that outperforms non-invasive procedures but is less invasive than traditional surgery – they are often called the “in-between” patient.
ThermiRF is an advanced technology using finely controlled thermal energy. It is a multi-use platform, which promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market. The device has been cleared by the FDA for dermatological and general surgical applications in soft tissue, and for lesioning of nerves.

Vitamin C+ Antiaging Booster Brighter by Exuviance

NeoStrata Company, Inc., Princeton, NJ, the creator of the original Glycolic Acid peel, is pleased to announce the debut of Vitamin C+ Antiaging Booster, available February 1, 2014. The new dermatologist developed product is the latest and most technologically advanced treatment for helping to smooth wrinkles and brighten dark spots improving skin texture and luminosity.
Vitamin C has been a “go-to” topical antiaging treatment for years, but has struggled with potency concerns over time, especially after opening. Studies show that the vitamin can deteriorate when exposed to light or air. That’s all changed with Exuviance Vitamin C+ Antiaging Booster, which uses a stable, 100% pure active powder formulation.
The antiaging power lies in pure vitamin C, essential for creating skin-firming and wrinkle-reducing collagen. Vitamin C helps restore luminosity while protecting skin from aging free radicals. Plus, patented Aceta-C improves the benefits of vitamin C targeting melanin to brighten brown spots and discolorations. The unique, stability-enhanced formulation is an anhydrous powder, contained in an opaque container with a shaker top, perfect for combining the correct dose into a serum or moisturizer just prior to use.

Steroid Creams vs Occlusivity and Moisturizing Potential of Cloderm

Promius Pharma® LLC, Bridgewater, NJ, has recently conducted two studies to measure the effect on skin barrier function after usage of Cloderm® (clocortolone pivalate) Cream 0.1%. The studies examined transepidermal water loss (TEWL) and skin hydration.
To determine and compare the occlusivity and moisturization potential of the test products, the products were applied to dry-razor shaved skin with disrupted skin barrier integrity in each study. Eighteen volunteers, 23–55 years of age, enrolled in, and completed, each study. They had no other skin conditions other than dry skin on the volar forearms.
According to lead investigator, Leon Kircik, MD, FAAD, of Mount Sinai Medical Center, NY and DermResearch, PLLC, Louisville, KY, “We now understand that epidermal barrier dysregulation plays an important role in the pathogenesis of atopic dermatitis, along with immunologic factors. It is important to utilize topical corticosteroids in vehicles that will help, at least to maintain, if not repair, the already disrupted epidermal barrier in atopic dermatitis patients.”
Using the skin trauma that occurs after dry-razor shaving in a bioassay provided skin sites that had increased TEWL and decreased skin surface hydration levels compared to normal skin sites. Although experimentally induced, the model is useful to determine the occlusive and moisturizing potential of topical products. The products tested in these studies all contain occlusive and humectant ingredients. However, the studies revealed that application of Cloderm Cream to skin after dry-razor shaving resulted in better hydration than Locoid® Lipocream and Locoid® Lotion. The TEWL results revealed that Cloderm Cream and Locoid® Lipocream had comparable occlusive effect and Locoid® Lotion did not